About Us

We build the medicines we wish existed

CPTx is a genetic medicines company redefining how we treat disease using immune-silent, redosable ssDNA as the foundation for safe, durable in vivo therapies.

Our lead program is a new kind of in vivo CAR-T cell therapy using immune-silent ssDNA delivered with LNPs, enabling repeat dosing, and controllable long lasting effects. Through alliances with innovative companies, we are also collaborating to develop novel genetic medicines. And CPTx is more than a pipeline or platform. Through gxstrands, our internal CDMO, we manufacture the industry’s most advanced ssDNA constructs, enabling partnerships and platforms that reach beyond our own products.

A story of progress

Our mission is to make complex genetic medicines safe, scalable, and accessible, starting with in vivo CAR-T.

We believe in a world where cell and gene therapies do not require a hospital bed or a million-dollar price tag. Our science is built to go over barriers and raise standards.

How we work

  • Platform-enabled: We design novel delivery and expression technologies as the foundation for our therapies.
  • Pipeline-focused: We translate proprietary science into differentiated therapeutic candidates, advancing rapidly toward the clinic.
  • End-to-end control: We integrate molecular engineering with in-house manufacturing to accelerate development timelines.
  • Strategic collaboration: We partner with biopharma leaders who share our commitment to precision, speed, and impact.

Pipeline, platform, and production 
under one roof.

CPTx unites world-class ssDNA engineering, seasoned drug developers, and manufacturing to bring innovative genetic medicines from the laboratory to the clinic.

Meet the Team

A team of experts

+

Hendrik Dietz

CEO & Founder

Hendrik Dietz

CEO & Founder

Dr. Hendrik Dietz founded CPTx in 2021 to carry forward 15 years of research and development of single stranded DNA programming and manufacturing processes. Committed to transforming theoretical ideas into practical applications, at CPTx he has assembled the talent and infrastructure needed to advance this work to solve deep challenges in the field of genetic medicines. Prior to CPTx, Dr. Dietz held faculty and research positions at Technical University of Munich (TUM) and Harvard School of Medicine, and is the recipient of numerous honors and awards, including the Gottfried Wilhelm Leibniz Prize. He received a PhD in Physics from TUM.

+

Grant Boldt

COO

Grant Boldt

COO

Dr. Grant Boldt joined as Chief Operating Officer in early 2024 and brings years of organizational and scientific leadership experience. Prior to joining the team, he was an executive in the pharmaceutical manufacturing and biotechnology sectors, including roles as Vice President (VP) of Research Pharmaceuticals at Sigma-Aldrich, Senior VP and Business Unit Head of Biologics at Lonza, and Executive VP of Biologics at Avantor. Dr. Boldt has been a frequent author and speaker throughout his career with a focus on advancing innovative scientific ideas into progress-driving applications. He received a PhD in Chemical Biology from Scripps Research Institute.

+

McDavid Stilwell

Chief Financial Officer

McDavid Stilwell

Chief Financial Officer

McDavid Stilwell became Chief Financial Officer in early 2025 and brings more than 25 years of experience in finance, corporate development, investor relations and communications. He was previously CFO at Coherus Biosciences during a period in which the company launched multiple new products into the U.S. market. Earlier he held senior leadership roles at Sangamo Therapeutics, Orexigen Therapeutics, and GTx, Inc. Prior to entering the biopharmaceutical industry, he was senior analyst at Shadwell Capital, a hedge fund, and he also worked several years as a journalist. His cross-functional expertise is critical to continuing to build the internal and external foundation of the company. He received a MBA from Harvard Business School.

+

Stefan Oschmann

Chairman of the Board

Stefan Oschmann

Chairman of the Board

Dr. Oschmann is a seasoned executive with extensive experience in biopharma, life science tools, and specialty chemicals. He was the Chairman and CEO at Merck KGaA, where he spearheaded the company’s transformation into a leading science and technology firm. Under his leadership, Merck introduced two blockbuster products in neuroscience and oncology. Following his seven-year tenure at Merck, he became chairman of UCB and AiCuris, and he currently works as a partner at the private equity firm Armira. His earlier career included senior roles at Merck & Co. (MSD), including President of Emerging Markets and President of Europe/Middle East/Africa, after starting in R&D at MSD and working in research at the International Atomic Energy Agency. He earned a doctorate (DVM) from the University of Munich.

A scientific foundation

We are scientists, engineers, and builders who have spent our careers turning synthetic biology into real medicine. We have launched products, scaled biomanufacturing, and led platform development from seed to clinic.

We set out in 2021 to translate more than 15 years of foundational research into ssDNA engineering, programming and manufacturing into a company pioneering the development of novel genetic medicines. With headquarters, labs, and manufacturing in Munich, Germany, and an office in South San Francisco, California, we are leading the field of single-stranded DNA engineering, synthesis, and therapeutics development, built on a deep body of peer-reviewed research and robust intellectual property and know-how.

 

Does building next generation in vivo CAR-T therapies interest you?

Reach out any time to express interest in joining our team, partnering, or investing.

Get in Touch